Effects of pioglitazone on insulin sensitivity and function of pancreatic a and ß cells in type 2 diabetic patients with different body weight

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17011571

Enrollment

Unknown

Registered

2017-06-05

Start date

2012-06-28

Completion date

Unknown

Last updated

2017-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

obese:Pioglitazone

non-obese:Pioglitazone

Eligibility

Sex/Gender

All

Age

31 Years to 63 Years

Inclusion criteria

Inclusion criteria: 1. Aged 25~60 years; 2. Duration: drug na?ve, newly diagnosed diabetic patients; 3. Subjects with BMI<24 and ?24 half by half (2~3 cases of low BMI group and high BMI group for each center). The percentage of adipose tissue will be measured by the body fat assessment machine; 4. FPG no more than 11mmol/L.

Exclusion criteria

Exclusion criteria: 1. FPG more than 11mmol/L; 2. type 1 diabetes; 3. DKA, infection and other stress status; 4. Autoimmune disease; 5. Hepatic and renal diseases; 6. Caner or Carcinoma; 7. The patients with severe HF (NYHA III & IV), symptomatic heart failure (edema or shortness of breath); 8. The patients with established edema; 9. The patients with increased risk of fractures.

Design outcomes

Primary

Measure	Time frame
plasma glucose;HbA1c;plasma insulin level;plasma glucagon;	—

Secondary

Measure	Time frame
leptin;adiponectin;CRP;	—

Countries

China

Contacts

Public ContactLi Guangwei

Fuwai Hospital, Chinese Academy of Medical Sciences

guangwei_li45@126.com+86 13911193892

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 7, 2026